| Web Results |
|
Tyrosinemia - Wikipedia, the free encyclopedia
|
||
|
Tyrosinemia is a genetic disorder characterized by elevated blood levels of the amino acid tyrosine, a building block of most proteins. Tyrosinemia is caused by the shortage (deficiency) of one of the enzymes required for the multistep process that breaks down tyrosine.
|
||
|
The portal for rare diseases and orphan drugs ... Fumarylacetoacetase deficiency; Hepatorenal tyrosinemia; ... Tyrosinemia type 1 is an inborn error of amino acid metabolism characterized by hepatorenal manifestations. Prevalence is estimated at 1 in 2 million.
|
||
|
Symptoms of Tyrosinemia including 26 medical symptoms and signs of Tyrosinemia, alternative diagnoses, misdiagnosis, and correct diagnosis for Tyrosinemia signs or Tyrosinemia symptoms. ... The list of signs and symptoms mentioned in various sources for Tyrosinemia includes the 26 symptoms listed below:
|
||
|
Elevated blood tyrosine levels are associated with several clinical entities. The term tyrosinemia was first given to a ... Excerpt from Tyrosinemia...
|
||
|
Elevated blood tyrosine levels are associated with several clinical entities. The term tyrosinemia was first given to a ... Transient tyrosinemia is believed to result from delayed enzyme maturation in the tyrosine catabolic pathway. This condition is essentially benign and spontaneously disappears with no sequelae.
|
||
|
Tyrosinemia is an inborn error of metabolism associated with severe liver disease in infancy. The disease is inherited in an autosomal recessive fashion, which means that both parents must be carriers of the gene for the disease.
|
||
|
Type I tyrosinemia ... Type I tyrosinemia () is the most severe form of this disorder and is caused by a shortage of the enzyme fumarylacetoacetate hydrolase (), encoded by the gene FAH found on chromosome number 15. Fumarylacetoacetate hydrolase is the last in a series of five enzymes needed to break down tyrosine.
|
||
|
Tyrosinemia Type I was described in 1957 and is caused by deficiency of fumarylacetoacetate hydrolase (FAH). While a predominance of patients are of French Canadian or Scandinavian decent, people from other ethnic groups have also been diagnosed.
|